
Pfizer Inc
PFEHealthcare|Drug Manufacturers - General|USA
$27.83
-0.49 (-1.73%)
DCF (FCF)
$43.06
Earnings Power
$22.11
Upcoming Data Readouts (45)
Oct 2026
Est. completion
P2Atopic Dermatitis
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964n=340
Oct 2026
Est. completion
Dec 2026
Est. completion
Dec 2026
Est. completion
Dec 2026
Est. completion
P1Healthy Participants
A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
NCT07231991n=24
Dec 2026
Est. completion
P2Urothelial Carcinoma
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329n=372
Dec 2026
Est. completion
P2Lymphoma, Non-Hodgkin
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
NCT03297606n=720
Dec 2026
Est. completion
P4Metastatic Urothelial Carcinoma
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
NCT06862219n=100
Jan 2027
Est. completion
P2Mycosis Fungoides
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
NCT05357794n=30
May 2027
Est. completion
P1Melanoma
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130n=124
Jun 2027
Est. completion
P1Carcinoma, Non-Small Cell Lung
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632n=1,006
Jul 2027
Est. completion
P1Myelodysplastic Syndrome
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847n=178
Jul 2027
Est. completion
Respiratory Syncytial Viruses
Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
NCT06813872n=1
Aug 2027
Est. completion
P1Acute Treatment of Migraine
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
NCT06995729n=16
Sep 2027
Est. completion
Dec 2027
Est. completion
P3ISS
Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.
NCT07226089n=254
Dec 2027
Est. completion
P2Prostate Adenocarcinoma
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
NCT06330805n=70
Dec 2027
Est. completion
P2Lymphoma, Non-Hodgkin
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535n=4,200
Dec 2027
Est. completion
P1Metastatic Breast Cancer
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT05508906n=190
Dec 2027
Est. completion
Advanced Breast Cancer
Southeast Netherlands Advanced Metastatic Breast Cancer Registry
NCT03577197n=7,000
Awaiting Results (29)
Trials past primary completion date but still active — data readout may be imminent.
Sep 2026
P2
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Sep 2026
P1P2
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
NCT05548127Jun 2026
P3
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295Jun 2026
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
NCT06678555Jun 2026
P1P2
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT04039230May 2026
P2
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Mar 2026
P1P2
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
NCT03786081Mar 2026
P1
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
NCT06974734